Your browser doesn't support javascript.
loading
Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab.
Ungar, B; Kopylov, U; Engel, T; Yavzori, M; Fudim, E; Picard, O; Lang, A; Williet, N; Paul, S; Chowers, Y; Bar-Gil Shitrit, A; Eliakim, R; Ben-Horin, S; Roblin, X.
Afiliação
  • Ungar B; Department of Gastroenterology, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
  • Kopylov U; Department of Gastroenterology, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
  • Engel T; Department of Gastroenterology, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
  • Yavzori M; Department of Gastroenterology, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
  • Fudim E; Department of Gastroenterology, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
  • Picard O; Department of Gastroenterology, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
  • Lang A; Department of Gastroenterology, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
  • Williet N; Service de Gastrologie-Entérologie-Hépatologie, CHU de Saint-Etienne, Saint-Etienne, France.
  • Paul S; Service de Gastrologie-Entérologie-Hépatologie, CHU de Saint-Etienne, Saint-Etienne, France.
  • Chowers Y; Rambam Health Care Campus, Bruce & Ruth Rappaport School of Medicine, Technion Institute of Technology, Haifa, Israel.
  • Bar-Gil Shitrit A; Digestive Diseases Institute, Shaare Zedek Medical Center, Jerusalem, Israel.
  • Eliakim R; Department of Gastroenterology, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
  • Ben-Horin S; Department of Gastroenterology, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
  • Roblin X; Service de Gastrologie-Entérologie-Hépatologie, CHU de Saint-Etienne, Saint-Etienne, France.
Aliment Pharmacol Ther ; 45(2): 276-282, 2017 01.
Article em En | MEDLINE | ID: mdl-27862102
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Colite Ulcerativa / Doença de Crohn / Adalimumab / Fatores Imunológicos / Anti-Inflamatórios / Formação de Anticorpos Tipo de estudo: Observational_studies / Prognostic_studies Limite: Adult / Female / Humans / Male Idioma: En Revista: Aliment Pharmacol Ther Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Colite Ulcerativa / Doença de Crohn / Adalimumab / Fatores Imunológicos / Anti-Inflamatórios / Formação de Anticorpos Tipo de estudo: Observational_studies / Prognostic_studies Limite: Adult / Female / Humans / Male Idioma: En Revista: Aliment Pharmacol Ther Ano de publicação: 2017 Tipo de documento: Article